Analyst Ratings for Krystal Biotech
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 11 analysts have published bullish opinions on Krystal Biotech (NASDAQ:KRYS) stock, with an average price target of $140.45, implying an upside from the current price of $113.635. The average price target has increased by 16.92% over the past month.
August 08, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have given bullish ratings to Krystal Biotech, with an average price target of $140.45, indicating potential upside from the current price.
The bullish ratings from 11 analysts over the past 3 months and the average price target which is higher than the current price indicate a positive outlook for Krystal Biotech. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100